Other Published Summaries of Treatment Outcomes
Other Published Summaries of Treatment Outcomes
Page last checked: 17th March 2023
Last updated: 22nd February 2022
October 2020: Independent Real-World Study Demonstrates Significant Improvements for Adults who have SMA Type 3, Treated with Nusinersen
In response to a request from SMA Europe, Biogen sent this community update which includes the observation that the most relevant treatment effect was seen in those with SMA Type 3 who were unable to walk without assistance at the start of treatment:
Read more >
June 2020: Further small studies support the use of nusinersen for SMA treatment in adults.
Three scientific reports have been published that present observations of adults who have SMA treated with repeated injections of nusinersen into the fluid bathing the spinal cord and brain.
Read more >
March 2020: Study Shows Nusinersen is Safe and Effective for SMA Treatment in Adults
A study in a large cohort of adults with SMA Types 1 to 3, indicates that nusinersen is safe and effective at improving muscle function. Published in the Lancet, this study was observational in design and conducted in Germany.
Read more >
October 2019: Two New Studies Show Positive Effects of Nusinersen in Later-Onset SMA
Two small, observational studies of the effects of nusinersen in patients with later-onset SMA have recently been published, both of which describe clinically meaningful improvements caused by the treatment. Read more in this article from our Scientific Research Correspondent, Dr James Sleigh: